OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study

• Published in: Journal of neurology 2023-02, Vol.270 (2), p.986-994
• Main Authors: Altamura, Claudia, Ornello, R., Ahmed, F., Negro, A., Miscio, A. M., Santoro, A., Alpuente, A., Russo, A., Silvestro, M., Cevoli, S., Brunelli, N., Grazzi, L., Baraldi, C., Guerzoni, S., Andreou, A. P., Lambru, G., Frattale, I., Kamm, K., Ruscheweyh, R., Russo, M., Torelli, P., Filatova, E., Latysheva, N., Gryglas-Dworak, A., Straburzynski, M., Butera, C., Colombo, B., Filippi, M., Pozo-Rosich, P., Martelletti, P., Sacco, S., Vernieri, F.
• Format: Article
• Language: English
• Subjects: Aged; Botulinum toxin type A; Botulinum Toxins, Type A - therapeutic use; Chronic Disease; Female; Geriatrics; Headache; Headache - drug therapy; Humans; Male; Medicine; Medicine & Public Health; Migraine; Migraine Disorders - drug therapy; Migraine Disorders - epidemiology; Neurology; Neuroradiology; Neurosciences; Original Communication; Preventive medicine; Treatment Outcome
• ISSN: 0340-5354; 1432-1459
• DOI: 10.1007/s00415-022-11457-5

Introduction Although migraine prevalence decreases with aging, some older patients still suffer from chronic migraine (CM). This study aimed to investigate the outcome of OnabotulinumtoxinA (OBT-A) as preventative therapy in elderly CM patients. Methods This is a post hoc analysis of real-life prospectively collected data at 16 European headache centers on CM patients treated with OBT-A over the first three treatment cycles (i.e., Cy1-3). We defined: OLD patients aged ≥ 65 years and nonOLD those